鲁卡帕利对比标准化疗治疗复发性卵巢癌伴BRCA1或BRCA2有害突变患者(ARIEL4):一项国际、开放标签、随机、3期试验
ARIEL4研究在12个国家64家中心随机分配349例既往接受≥2线化疗的BRCA1/2突变复发性卵巢癌患者,2:1接受鲁卡帕利或化疗。疗效人群中位PFS鲁卡帕利组7.4个月 vs 化疗组5.7个月(HR 0.64,P=0.0010)。结果支持鲁卡帕利作为化疗的替代选择。
要点
- 疗效人群鲁卡帕利组中位PFS 7.4个月 vs 化疗组5.7个月,HR 0.64(95%CI 0.49-0.84),P=0.0010。
- 意向治疗人群鲁卡帕利组中位PFS 7.4个月 vs 化疗组5.7个月,HR 0.67(95%CI 0.52-0.86),P=0.0017。
- ≥3级治疗中出现的不良事件最常见为贫血或血红蛋白降低,鲁卡帕利组22% vs 化疗组5%。
核心结论
- ARIEL4研究结果支持鲁卡帕利作为复发性BRCA1或BRCA2突变卵巢癌患者化疗的替代治疗选择。
研究设计与样本
- 国际、开放标签、随机、对照3期试验,在12个国家64家医院和癌症中心开展。
- 纳入年龄≥18岁、BRCA1或BRCA2突变卵巢癌、ECOG体能状态0或1、既往接受≥2线化疗的患者。
- 349例合格患者按2:1随机分配至口服鲁卡帕利600 mg每日两次组(n=233)或化疗组(n=116),按末次含铂治疗后无进展间期分层。
- 化疗组中铂耐药或部分铂敏感者接受紫杉醇(起始剂量60-80 mg/m²,第1、8、15天给药),完全铂敏感者接受含铂化疗(单药顺铂或卡铂,或铂双药化疗)。
- 主要终点为研究者评估的无进展生存期,先在疗效人群(所有随机分配且无回复突变的BRCA1/2有害突变患者)中评估,再在意向治疗人群中评估。
主要发现
- 2017年3月1日至2020年9月24日筛查930例患者,349例随机分配至鲁卡帕利组(n=233)或化疗组(n=116)。
- 中位年龄58岁(IQR 52-64),332例(95%)为白人。
- 截至2020年9月30日数据截止,中位随访25.0个月(IQR 13.8-32.5)。
- 疗效人群(鲁卡帕利组220例,化疗组105例)中位PFS:鲁卡帕利组7.4个月(95%CI 7.3-9.1) vs 化疗组5.7个月(95%CI 5.5-7.3),HR 0.64(95%CI 0.49-0.84),P=0.0010。
- 意向治疗人群(鲁卡帕利组233例,化疗组116例)中位PFS:鲁卡帕利组7.4个月(95%CI 6.7-7.9) vs 化疗组5.7个月(95%CI 5.5-6.7),HR 0.67(95%CI 0.52-0.86),P=0.0017。
关键数值与推荐
- 鲁卡帕利组剂量为口服600 mg每日两次;化疗组紫杉醇起始剂量60-80 mg/m²,第1、8、15天给药。
- 疗效人群中位PFS鲁卡帕利组7.4个月 vs 化疗组5.7个月,HR 0.64(95%CI 0.49-0.84),P=0.0010。
- 意向治疗人群中位PFS鲁卡帕利组7.4个月 vs 化疗组5.7个月,HR 0.67(95%CI 0.52-0.86),P=0.0017。
- ≥3级治疗中出现的不良事件最常见为贫血或血红蛋白降低:鲁卡帕利组52/232例(22%) vs 化疗组6/113例(5%)。
- 严重治疗中出现的不良事件:鲁卡帕利组62/232例(27%) vs 化疗组13/113例(12%);研究者认为与治疗相关的严重不良事件:鲁卡帕利组32/232例(14%) vs 化疗组6/113例(5%)。
临床怎么用
- 作者认为,ARIEL4研究结果支持鲁卡帕利作为复发性BRCA1或BRCA2突变卵巢癌患者化疗的替代治疗选择。
- 大多数治疗中出现的不良事件为1级或2级。
- 3例死亡被认为可能与鲁卡帕利相关(1例心脏疾病,1例骨髓增生异常综合征,1例原因未确认)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few prospective studies have compared poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or BRCA2-mutated ovarian carcinoma. We aimed to assess rucaparib versus platinum-based and non-platinum-based chemotherapy in this setting. METHODS: In this open-label, randomised, controlled, phase 3 study (ARIEL4), conducted in 64 hospitals and cancer centres across 12 countries (Brazil, Canada, Czech Republic, Hungary, Israel, Italy, Poland, Russia, Spain, Ukraine, the UK, and the USA), we recruited patients aged 18 years and older with BRCA1-mutated or BRCA2-mutated ovarian carcinoma, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had received two or more previous chemotherapy regimens. Eligible patients were randomly assigned (2:1), using an interactive response technology and block randomisation (block size of six) and stratified by progression-free interval after the most recent platinum-containing therapy, to oral rucaparib (600 mg twice daily) or chemotherapy (administered per institutional guidelines). Patients assigned to the chemotherapy group with platinum-resistant or partially platinum-sensitive disease were given paclitaxel (starting dose 60-80 mg/m2 on days 1, 8, and 15); those with fully platinum-sensitive disease received platinum-based chemotherapy (single-agent cisplatin or carboplatin, or platinum-doublet chemotherapy). Patients were treated in 21-day or 28-day cycles. The primary endpoint was investigator-assessed progression-free survival, assessed in the efficacy population (all randomly assigned patients with deleterious BRCA1 or BRCA2 mutations without reversion mutations), and then in the intention-to-treat population (all randomly assigned patients). Safety was assessed in all patients who received at least one dose of assigned study treatment. This study is registered with ClinicalTrials.gov, NCT02855944; enrolment is complete, and the study is ongoing. FINDINGS: Between March 1, 2017, and Sept 24, 2020, 930 patients were screened, of whom 349 eligible patients were randomly assigned to rucaparib (n=233) or chemotherapy (n=116). Median age was 58 years (IQR 52-64) and 332 (95%) patients were White. As of data cutoff (Sept 30, 2020), median follow-up was 25·0 months (IQR 13·8-32·5). In the efficacy population (220 patients in the rucaparib group; 105 in the chemotherapy group), median progression-free survival was 7·4 months (95% CI 7·3-9·1) in the rucaparib group versus 5·7 months (5·5-7·3) in the chemotherapy group (hazard ratio [HR] 0·64 [95% CI 0·49-0·84]; p=0·0010). In the intention-to-treat population (233 in the rucaparib group; 116 in the chemotherapy group), median progression-free survival was 7·4 months (95% CI 6·7-7·9) in the rucaparib group versus 5·7 months (5·5-6·7) in the chemotherapy group (HR 0·67 [95% CI 0·52-0·86]; p=0·0017). Most treatment-emergent adverse events were grade 1 or 2. The most common grade 3 or worse treatment-emergent adverse event was anaemia or decreased haemoglobin (in 52 [22%] of 232 patients in the rucaparib group vs six [5%] of 113 in the chemotherapy group). Serious treatment-emergent adverse events occurred in 62 (27%) patients in the rucaparib group versus 13 (12%) in the chemotherapy group; serious adverse events considered related to treatment by the investigator occurred in 32 (14%) patients in the rucaparib group and six (5%) in the chemotherapy group. Three deaths were considered to be potentially related to rucaparib (one due to cardiac disorder, one due to myelodysplastic syndrome, and one with an unconfirmed cause). INTERPRETATION: Results from the ARIEL4 study support rucaparib as an alternative treatment option to chemotherapy for patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian carcinoma. FUNDING: Clovis Oncology.
引用
- Kristeleit R, Lisyanskaya A, Fedenko A, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2022. PMID: 35298906. doi:10.1016/S1470-2045(22)00122-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。